OakChart

Absci Corp

ABSIHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 8:28 AM ET

10.49+0.52 (5.22%)
2026-11-11 14:31 CET
Market cap
1,710.99 USD m
Revenue, TTM
1.56 USD m
Net income, TTM
-121.08 USD m
Free cash flow, TTM
-108.97 USD m
EPS diluted, TTM
-0.80
P/E
-
Compare

Price

ABSI against its 20, 50 and 200-day averages
2050200earnings
5.007.5010.0012.5019.1M38.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ABSIclose 10.4920-day 9.9750-day 9.66200-day 6.7710.49

16.4% under 12.55 on 29 Oct 2026. Last 15 sessions, 40.5% high to low

Profile

ABSI
52-week range, 80% of the way up
2.2412.54

Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

IndexRUT
Employees140
IPOJul 22, 2021
Beta2.20
ATR, 14d1.03
Rel volume0.07
Short float24.19%
Insider own13.68%
Inst own84.26%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.80B
Enterprise Value1.60B
Income-121.08M
Sales1.56M
Book/sh1.43
Cash/sh1.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees140
IPOJul 22, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1153.99
P/B7.31
P/C8.95
P/FCF-
EV/EBITDA-
EV/Sales1027.51
Quick Ratio10.63
Current Ratio10.63
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.80
EPS next Y-0.74
EPS next Q-0.19
EPS this Y5.15%
EPS next Y7.30%
EPS next 5Y10.61%
EPS past 3/5Y9.99% -9.45%
Sales past 3/5Y-21.31% -10.14%
EPS Y/Y TTM15.36%
Sales Y/Y TTM-62.28%
EPS Q/Q11.98%
Sales Q/Q-46.37%
EarningsNov 12 BMO
EPS/Sales Surpr.-9.95% -67.38%

Ownership

Insider Own13.68%
Insider Trans0.21%
Inst Own84.26%
Inst Trans18.66%
ROA-50.57%
ROE-57.72%
ROIC-48.87%
Gross Margin-610.70%
Oper. Margin-8411.27%
Profit Margin-7756.37%
SMA205.19%
SMA508.57%
SMA20054.84%
Trades-

Technical

Shs Outstand171.56M
Shs Float148.14M
Short Float24.19%
Short Ratio9.57
Short Interest35.84M
52W High12.54 -16.38%
52W Low2.24 368.30%
Volatility11.11% 10.24%
ATR (14)1.03
RSI (14)52.69
Beta2.20
Rel Volume0.07
Avg Volume3.74M
Volume12,825

Performance

Perf Week0.10%
Perf Month15.27%
Perf Quarter10.89%
Perf Half Y97.92%
Perf YTD200.57%
Perf Year204.06%
Perf 3Y725.98%
Perf 5Y-19.06%
Perf 10Y-
Recom1.17
Target Price14.82
Prev Close9.97
Price10.49
Change %5.22%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 29, 2026InitiatedJJefferiesBuy$14+33.5%
Jun 04, 2026InitiatedLLeerink PartnersOutperform$12+14.4%
May 28, 2026InitiatedBBTIG ResearchBuy$9-14.2%
Jan 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$4.32-58.8%
Oct 02, 2025InitiatedJJP MorganOverweight
Jul 03, 2025ResumedMMorgan StanleyOverweight$7-33.3%
Jan 22, 2025InitiatedNNeedhamBuy$9-14.2%
Oct 02, 2024InitiatedGGuggenheimBuy$10-4.7%
Jul 03, 2024InitiatedMMorgan StanleyOverweight$7-33.3%
Mar 14, 2024InitiatedBScotiabankSector Outperform$13+23.9%

Peers

Mkt cap
TickerCompanyMkt cap
GENBGenerate Biomedicines Inc1.66B
ABCLAbCellera Biologics Inc4.15B
RXRXRecursion Pharmaceuticals Inc2.32B
SDGRSchrodinger Inc2.50B
XNCRXencor Inc2.96B
TWSTTwist Bioscience Corp9.24B
DNAGinkgo Bioworks Holdings Inc824.24M
MANEVeradermics Inc6.23B
CERTCertara Inc1.89B
EVAXEvaxion A/S ADR22.80M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM

Held by

AUM
TickerCompanyAUM
ARKGARK Genomic Revolution ETFAUM: 2.07B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWOiShares Russell 2000 Growth ETFAUM: 14.20B
IBBiShares Biotechnology ETFAUM: 11.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.36B

News

latest 14 of 206
  • Absci's Third-Quarter Report Puts ABS-201 Hair-Loss Readout Timing In The Spotlight (Earnings Whispers)
  • Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.85%
  • Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026 (GlobeNewswire) -5.89%
  • Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis (GlobeNewswire) +6.16%
  • AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 (PR Newswire)
  • Loading…
  • Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade (BeInCrypto)
  • Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Earnings To Watch: Absci Corp (ABSI) Q2 2026 -- GF Value Sees 92% Downside (GuruFocus.com)
  • A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed (PR Newswire) -6.32%
  • As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 (PR Newswire)
  • Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 (GlobeNewswire)
  • As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.189--0.6311
2026Q22026-08-11-0.210-0.191-0.2100.300.929
2026Q12026-05-07-0.190-0.199-0.1940.221.269
2025Q42026-03-24-0.200-0.178-0.1960.651.429
2025Q32025-11-12-0.200-0.205-0.2000.381.588
2025Q22025-08-12-0.240-0.209-0.2400.591.267
2025Q12025-05-13-0.210-0.224-0.2121.181.507
2024Q42025-03-18-0.250-0.224-0.2530.671.779
2024Q32024-11-12-0.240-0.194-0.2411.701.757
2024Q22024-08-14-0.220-0.181-0.2191.271.917
2024Q12024-05-14-0.220-0.212-0.2210.902.106
2023Q42024-03-21-0.250-0.213-0.2540.340.904
2023Q32023-11-14-0.240-0.230-0.2390.743.004
2023Q22023-08-14-0.450-0.238-0.4543.402.445
2023Q12023-05-15-0.260-0.232-0.2551.272.256
2022Q42023-03-30-0.210-0.252-0.2131.564.736

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.080-1.900-1.1144.785.05
2022FY-1.150-1.166-1.1555.759.31
2023FY-1.200-1.083-1.2015.726.40
2024FY-0.940-0.864-0.9354.536.05
2025FY-0.840-0.827-0.8802.803.61
2026FY--0.797--3.72
2027FY--0.739--14.66
2028FY--0.600--29.83
2029FY--0.494--33.94
2030FY--0.108--90.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2810010.630.001.72
2026Q3S2026-10-2710010.630.001.72
2026Q3S2026-10-269010.660.001.72
2026Q3S2026-10-149140.660.001.72
2026Q3S2026-09-239130.700.001.72
2026Q3S2026-08-129140.700.001.72
2026Q3S2026-08-119021.030.003.00
2026Q3S2026-07-229021.030.003.00
2026Q3S2026-07-119141.030.003.00
2026Q3S2026-07-109241.030.003.00
2026Q3S2026-07-079231.050.003.00
2026Q3S2026-07-029221.070.003.00
2026Q3S2026-06-0810221.060.003.00
2026Q3S2026-05-2710321.060.003.00

Estimate history

EPS, annual-0.259-0.536-1.114-1.155-1.201-0.935-0.842-0.8004
Period2019202020212022202320242025TTM
EPS, quarterly-0.219-0.241-0.253-0.212-0.24-0.2-0.196-0.194-0.211
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.064.784.7825.7475.7184.5342.81.56
Period2019202020212022202320242025TTM
Sales, quarterly1.271.7010.6651.1790.5930.3780.650.2150.318
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual92.2592.2592.64892.41193.088115.362151.515171.558
Period2019202020212022202320242025MRQ
Shares, quarterly113.444114.191115.362127.541127.677149.746151.515155.35171.558
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1.562.804.535.725.754.784.782.06
Cost of Goods Sold Incl. D&A11.0911.7413.3914.0013.046.65--
Gross Profit-9.53-8.94-8.86-8.28-7.29-1.87--
Selling, General and Administrative Excl. Other121.77115.78100.0385.4099.4672.4716.957.83
Research and Development86.4980.7263.8647.5758.9144.5911.454.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-131.30-124.72-108.89-93.68-106.75-74.34-13.30-6.26
Interest Expense0.090.210.561.010.973.430.630.27
Unusual Expense-5.10-4.400.0021.840.0035.110.460.00
Net Income Before Taxes-121.08-115.11-103.04-110.47-105.36-109.86-14.35-6.58
Income Taxes-0.000.070.070.10-0.46-8.900.000.00
Consolidated Net Income-121.08-115.18-103.11-110.57-104.90-100.96-14.35-6.58
Net Income From Continuing Operations-121.08-115.18-103.11-110.57-104.90-100.96-14.35-6.58
Net Income-121.08-115.18-103.11-110.57-104.90-103.24-49.47-23.87
EPS (Recurring)-0.79-0.86-0.94-1.04-1.15-0.85-0.53-0.26
EPS (Basic, Before Extraordinaries)-0.80-0.84-0.94-1.20-1.15-1.11-0.54-0.26
EPS (Diluted)-0.80-0.84-0.94-1.20-1.15-1.11-0.54-0.26
EBITDA-120.21-112.98-95.50-79.68-93.71-67.68-12.17-5.77
Non-Operating Income (Expense)5.225.416.426.062.363.020.04-0.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.4414.5015.389.0510.007.740.420.04
Price To Sales Ratio1,169.18170.4863.7067.6033.20158.87--
Gross Margin-610.70-319.36-195.30-144.82-126.85-39.15--
Operating Margin-8,411.27-4,454.21-2,401.59-1,638.34-1,857.49-1,554.54-278.26-304.13
Net Margin-7,756.37-4,113.68-2,274.06-1,933.65-1,825.37-2,159.01-1,034.92-1,158.74
Shares Outstanding171.56151.52115.3693.0992.4192.6592.2592.25
Market Capitalization1,710.991,710.99300.92390.34194.03759.25796.29-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.320.210.650.380.591.180.671.70
Cost of Goods Sold Incl. D&A2.702.732.832.843.003.073.233.35
Gross Profit-2.38-2.51-2.18-2.46-2.41-1.89-2.57-1.65
Selling, General and Administrative Excl. Other31.7828.3333.9627.6928.9925.8427.2027.24
Research and Development22.6219.2725.3519.2520.4616.3618.3817.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.16-30.85-36.14-30.15-31.39-27.73-29.77-28.89
Interest Expense0.000.020.030.040.060.080.110.13
Unusual Expense0.000.00-5.100.000.000.000.000.00
Net Income Before Taxes-33.17-29.58-29.72-28.60-30.44-26.35-28.96-27.36
Income Taxes0.040.02-0.160.100.13-0.000.020.04
Consolidated Net Income-33.21-29.60-29.56-28.71-30.57-26.35-28.98-27.40
Net Income From Continuing Operations-33.21-29.60-29.56-28.71-30.57-26.35-28.98-27.40
Net Income-33.21-29.60-29.56-28.71-30.57-26.35-28.98-27.40
EPS (Recurring)-0.21-0.19-0.22-0.20-0.24-0.21-0.25-0.24
EPS (Basic, Before Extraordinaries)-0.21-0.19-0.20-0.20-0.24-0.21-0.25-0.24
EPS (Diluted)-0.21-0.19-0.20-0.20-0.24-0.21-0.25-0.24
EBITDA-31.46-28.12-33.31-27.31-28.39-24.66-26.54-25.54
Non-Operating Income (Expense)0.991.281.351.601.011.460.921.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.143.463.363.473.753.904.004.35
Price To Sales Ratio1,169.18249.94187.73155.2679.2464.8866.15103.16
Gross Margin-747.80-1,168.84-335.08-651.85-405.90-160.56-386.32-97.24
Operating Margin-10,741.51-14,346.98-5,560.31-7,977.25-5,293.93-2,351.91-4,477.29-1,698.71
Net Margin-10,443.40-13,766.98-4,548.00-7,594.18-5,154.97-2,234.61-4,358.35-1,610.70
Shares Outstanding171.56155.35151.52149.75127.68127.54115.36114.19
Market Capitalization1,710.99459.06524.80454.55327.83319.61300.92433.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments144.29128.37113.85179.45263.0869.8713.09
Short Term Receivables0.000.002.191.551.431.590.22
Inventories0.000.000.000.000.000.000.00
Other Current Assets5.285.464.545.868.571.770.34
Total Current Assets149.57133.83120.58186.86273.0873.2313.65
Net Property, Plant & Equipment23.7733.1345.8258.0458.6513.385.01
Total Investments and Advances1.051.051.111.8616.841.840.79
Intangible Assets41.5144.8848.2572.9676.33--
Deferred Tax Assets--17.1817.66---
Other Assets0.380.701.541.281.290.110.02
Total Assets216.30213.61234.48338.67426.1988.5719.47
Short Term Debt Incl. Current Port. of LT Debt2.684.425.586.936.693.781.89
Accounts Payable2.763.531.502.418.382.120.27
Other Current Liabilities17.3320.7122.4820.9318.794.201.31
Total Current Liabilities22.7728.6629.5630.2733.8610.103.47
Long Term Debt2.625.6910.3816.0513.3210.724.13
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities--17.3717.900.74--
Other Liabilities1.460.131.000.0412.160.750.27
Total Liabilities26.8534.4858.3064.2560.0921.567.87
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00156.4352.76
Common Equity189.45179.13176.18274.41366.11-89.43-41.16
Total Shareholders Equity189.45179.13176.18274.41366.1167.0011.60
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity189.45179.13176.18274.41366.1167.0011.60
Total Liabilities & Stockholders Equity216.30213.61234.48338.67426.1988.5719.47
Book Value Per Share1.251.551.892.973.95-0.97-0.45
Tangible Book Value Per Share0.981.161.372.183.13-0.97-0.45
Full-Time Employees140157156193212169-
Price to Book Ratio6.951.491.990.672.082.05-
Return on Assets-53.59-46.02-38.58-27.43-39.23-26.57-
Return on Equity-62.50-58.04-49.08-32.76-46.62-36.52-
Return on Invested Capital-59.97-55.79-59.27-36.12-26.61-18.47-41.85
Quick Ratio6.574.674.086.178.077.253.94
Current Ratio6.574.674.086.178.077.253.94

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-121.08-115.18-103.11-110.57-104.90-100.96-14.35-6.58
Depreciation11.0911.7413.3914.0013.046.651.130.49
Other Funds (Non Cash)10.3010.0917.6830.4712.5745.761.240.15
Funds from Operations-99.68-93.35-72.03-66.15-79.80-57.45-11.98-5.94
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-8.400.42-0.371.52-1.54-3.151.01-0.09
Cash from Operating Activities-108.08-92.92-72.40-64.64-81.34-60.60-10.97-6.03
Capital Expenditures-0.89-1.11-0.40-0.86-16.18-38.05-2.18-1.10
Net Assets From Acquisitions0.000.000.000.00-8.00-28.130.000.00
Sale of Fixed Assets and Businesses0.171.310.940.250.130.000.010.01
Purchase or Sale of Investments-12.01-50.37-42.1182.55-103.59-1.200.000.00
Purchase of Investments-84.50-119.87-186.11-147.35-108.59-1.200.000.00
Sale Or Maturity of Investments72.4969.50144.00229.905.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.650.000.000.00
Cash from Investing Activities-12.72-50.16-41.5881.94-126.98-67.38-2.17-1.09
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock176.44109.1486.560.860.66215.3469.3310.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock176.44109.1486.560.860.66215.3469.3310.33
Proceedsfrom Stock Options176.44109.1486.560.860.66215.3469.3310.33
Issuance or Reduction of Debt, Net-2.00-3.20-4.03-5.344.58120.851.642.38
Change in Long Term Debt-2.00-3.20-4.03-5.344.58120.851.012.38
Issuance of Long Term Debt0.000.000.000.0012.03125.002.602.76
Reduction of Long Term Debt-2.00-3.20-4.03-5.34-7.45-4.15-1.59-0.38
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities174.44105.9582.53-4.485.24336.1970.9712.71
Net Change in Cash53.63-37.14-31.4512.82-203.08208.2257.835.58
Free Cash Flow-108.97-94.03-72.81-65.50-97.51-98.64-13.15-7.13
Preferred Dividends (Cash Flow)-0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.00-0.05-0.51-8.900.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments201.14125.70144.29168.82133.67150.06
Short Term Receivables0.000.000.001.000.701.38
Inventories0.000.000.000.000.000.00
Other Current Assets7.126.275.285.183.044.54
Total Current Assets208.27131.97149.57174.99137.40155.98
Net Property, Plant & Equipment19.1621.4123.7726.2127.5230.74
Total Investments and Advances1.051.061.051.051.051.05
Intangible Assets40.0540.7741.5142.3643.2044.04
Other Assets0.380.380.380.380.720.63
Total Assets268.92195.59216.30244.99209.89232.45
Short Term Debt Incl. Current Port. of LT Debt2.192.272.683.063.704.23
Accounts Payable7.168.822.764.598.214.95
Other Current Liabilities10.268.9417.3322.0619.4218.10
Total Current Liabilities19.6020.0322.7729.7131.3227.28
Long Term Debt1.642.152.623.163.714.68
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.551.451.461.791.481.69
Total Liabilities22.7923.6226.8534.6536.5233.65
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity246.13171.97189.45210.34173.37198.80
Total Shareholders Equity246.13171.97189.45210.34173.37198.80
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity246.13171.97189.45210.34173.37198.80
Total Liabilities & Stockholders Equity268.92195.59216.30244.99209.89232.45
Book Value Per Share1.431.111.251.401.361.56
Tangible Book Value Per Share1.200.840.981.121.021.21
Full-Time Employees--140---
Price to Book Ratio6.952.402.482.241.651.62
Return on Assets-50.57-55.34-53.59-47.73-48.69-42.37
Return on Equity-57.72-63.89-62.50-55.68-57.39-48.98
Return on Invested Capital-13.40-17.00-15.39-13.45-17.26-12.95
Quick Ratio10.636.596.575.894.395.72
Current Ratio10.636.596.575.894.395.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-33.21-29.60-29.56-28.71-30.57-26.35
Depreciation2.702.732.832.843.003.07
Other Funds (Non Cash)4.693.69-1.653.563.964.22
Funds from Operations-25.82-23.18-28.38-22.30-23.61-19.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.74-3.13-0.80-2.736.74-2.79
Cash from Operating Activities-27.56-26.31-29.18-25.03-16.87-21.84
Capital Expenditures-0.00-0.030.10-0.96-0.22-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.040.000.130.001.070.11
Purchase or Sale of Investments24.037.3919.32-62.748.19-15.13
Purchase of Investments-3.96-18.6115.01-76.93-17.81-40.13
Sale Or Maturity of Investments27.9926.004.3114.1926.0025.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities24.077.3619.55-63.709.04-15.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock102.998.024.3461.100.1043.60
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock102.998.024.3461.100.1043.60
Proceedsfrom Stock Options102.998.024.3461.100.1043.60
Issuance or Reduction of Debt, Net-0.26-0.46-0.50-0.78-1.11-0.81
Change in Long Term Debt-0.26-0.46-0.50-0.78-1.11-0.81
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.26-0.46-0.50-0.78-1.11-0.81
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities102.737.563.8460.32-1.0042.79
Net Change in Cash99.23-11.39-5.79-28.42-8.845.91
Free Cash Flow-27.57-26.34-29.08-25.99-17.10-21.86

Revenue breakdown

Services-Commercial Physical & Biological Research2024: 4.53M 2025: 2.80M
United States2024: 4.53M 2025: 2.80M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.19%35.8M148.1M3.55M
2026-10-1524.99%37.0M148.1M3.44M
2026-09-3025.28%37.4M148.1M3.49M
2026-09-1525.16%37.3M148.1M4.45M
2026-08-3124.89%36.8M147.8M4.84M
2026-08-1425.32%37.4M147.8M5.09M
2026-07-3125.40%37.3M146.9M5.57M
2026-07-1524.34%35.8M146.9M6.06M
2026-06-3025.48%36.9M145.0M5.86M
2026-06-1525.03%33.4M133.3M4.94M
2026-05-2924.06%32.1M133.3M4.64M
2026-05-1524.13%32.2M133.6M4.36M
2026-04-3025.01%33.7M134.8M4.00M
2026-04-1526.53%35.1M132.3M3.54M
2026-03-3128.13%37.3M132.7M3.67M
2026-03-1329.11%38.0M130.4M3.23M
2026-02-2729.52%38.5M130.4M3.43M
2026-02-1330.23%39.4M130.4M3.73M
2026-01-3027.37%37.3M136.1M4.02M
2026-01-1527.54%37.4M135.8M4.28M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.007.5011.009.470.0004.000.000.993-0.0130.000
call2.006.5010.008.380.00027.000.000.988-0.0140.001
call3.005.509.007.0515.9985360.000.984-0.0140.001
call4.004.508.006.3011.8633090.000.978-0.0140.001
call5.004.605.905.206.0001141.000.972-0.0140.001
call6.002.504.704.504.2942,7380.000.964-0.0130.001
call7.001.503.703.653.3932,3260.000.892-0.0320.003
call8.001.552.352.331.8612,4161.000.790-0.0520.005
call9.001.102.001.372.3662,29314.000.703-0.0460.006
call10.000.601.000.801.5491,34312.000.551-0.0550.006
call11.000.200.600.451.5062,78717.000.394-0.0490.006
call12.000.150.450.301.6771,3021050.297-0.0490.006
call13.000.150.250.201.6121,2051070.193-0.0370.004
call14.000.000.450.171.8818710.000.173-0.0400.004
call15.000.050.250.102.1186673.000.159-0.0430.004
call16.000.003.100.252.33239.000.000.149-0.0450.004
call17.000.000.600.852.52657.000.000.141-0.0470.004
call18.000.001.950.002.7040.000.000.134-0.0490.004
call19.000.002.700.002.8680.000.000.129-0.0500.003
call20.000.001.950.103.02114.000.000.124-0.0520.003
call21.000.001.000.003.1630.000.000.120-0.0530.003
call22.000.000.950.003.2970.000.000.117-0.0540.003
put1.000.000.050.007.6170.000.00-0.007-0.0120.000
put2.000.001.150.005.3860.000.00-0.012-0.0140.001
put3.000.002.750.144.0687.000.00-0.016-0.0140.001
put4.000.000.200.053.1602230.00-0.022-0.0140.001
put5.000.000.200.132.46149.000.00-0.028-0.0130.001
put6.000.000.200.041.88944.005.00-0.036-0.0120.001
put7.000.050.200.102.0213506.00-0.108-0.0310.003
put8.000.100.500.192.1411,1211.00-0.210-0.0510.005
put9.000.300.550.471.5551,14942.00-0.297-0.0450.006
put10.000.451.150.951.7514937.00-0.449-0.0540.006
put11.000.802.051.912.1794390.00-0.606-0.0470.006
put12.000.254.902.555.49139.000.00-0.703-0.0470.006
put13.001.004.900.004.3260.000.00-0.807-0.0360.004
put14.002.006.003.804.0452.000.00-0.827-0.0390.004
put15.003.005.506.502.6391.000.00-0.841-0.0410.004
put16.004.007.500.004.6040.000.00-0.851-0.0430.004
put17.005.008.500.004.8440.000.00-0.859-0.0450.004
put18.006.009.500.005.0630.000.00-0.866-0.0470.004
put19.007.0010.500.005.2650.000.00-0.871-0.0480.003
put20.008.0011.500.005.4520.000.00-0.876-0.0490.003
put21.009.0012.500.005.6260.000.00-0.880-0.0510.003
put22.0010.0013.500.005.7880.000.00-0.883-0.0520.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-03-03SEC
2026-08-073Initial statement of beneficial ownership of securities2026-03-03SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-24424B5SEC
2026-06-154/A2026-06-04SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-31SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-22SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06148.87K100
2026-05200.75K100
2026-040000
2026-03229.00K100
2026-02205.76K1132.33K2
2026-010000
2025-12148.80K100
2025-110000

Institutional holders

Manager% owned
FMR LLC15.00%
ARK Investment Management LLC8.29%
BlackRock, Inc.7.81%
STATE STREET CORP5.19%
AMERIPRISE FINANCIAL INC4.48%
Redmile Group, LLC4.32%
VANGUARD CAPITAL MANAGEMENT LLC3.93%
ADVANCED MICRO DEVICES INC3.67%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.66%
TWO SIGMA INVESTMENTS, LP3.52%

Funds

Fund% owned
ARK Genomic Revolution ETF6.07%
Fidelity Growth Company Fund4.68%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.32%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.83%
iShares Russell 2000 ETF2.28%
Columbia Acorn Fund1.85%
Fidelity Growth Company K6 Fund1.46%
Fidelity Series Growth Company Fund1.26%
VANGUARD EXTENDED MARKET INDEX FUND1.01%
ARK Venture Fund0.96%

OakChart. ABSI. Cached 15 minutes.